Kraig Biocraft Laboratories, Inc. has announced a pivotal production agreement to scale up its recombinant spider silk technology. This new partnership follows the recent introduction of the Company's advanced spider silk production hybrids and aims to enhance manufacturing capabilities.

Under the agreement, Kraig Labs will collaborate with established silk manufacturers to retrofit their facilities for producing the Company's proprietary spider silk. This strategic move includes the development of additional production sites to boost output and meet growing demand.

Kraig Labs Founder and CEO, Kim Thompson, highlighted the importance of the new agreement in advancing commercial-scale production. He noted the Company's dedication to increasing production capacity and unlocking the potential of spider silk. The agreement is seen as a crucial milestone in scaling up and fully realizing the benefits of their technology.

The agreement signifies a major advancement in Kraig Labs mission to establish a robust, large-scale spider silk manufacturing network.